Goldman Sachs Lowers PT on Medicis Pharmaceutical to $38

Symbols: MRX
Share

Goldman Sachs has lowered the price target on Medicis Pharmaceutical (NYSE: MRX) from $39 to $38 and maintains its Neutral rating.


 
 
< Previous
Piper Jaffray Lowers PT on Cavium to $16
Next >
JP Morgan Lowers PT on Cavium Networks to $37.50
Share
Printer-friendly version
Send to friend
We're Loving

Benzinga's Premium Memberships

Benzinga's News Delivered Free

Brain Trust